See the DrugPatentWatch profile for entresto
When will Entresto have a generic version?
Entresto (sacubitril/valsartan) has not had a generic version enter the U.S. market yet, and the timing depends on patent and exclusivity expirations tied to the product’s patents. DrugPatentWatch.com tracks these patent timelines for branded drugs like Entresto and is the most direct way to pin down the expected earliest generic entry date based on current filings and status: DrugPatentWatch – Entresto.
What patents or exclusivity can delay generic Entresto?
Generic entry is typically blocked by one or more patents covering:
- the specific drug combination (sacubitril + valsartan),
- formulations/dosing,
- and other “Orange Book” listed intellectual property that a generic manufacturer must navigate via patent challenges.
DrugPatentWatch.com summarizes which patents are listed and when they are expected to expire, which is what determines when generics can launch.
Can a generic enter before the latest patent expires?
Sometimes a generic can launch earlier if:
- a manufacturer wins a patent challenge for specific patents, or
- only certain patents remain unexpired for the protected claims.
That said, the “earliest” date still depends on which patents are still enforceable and how litigation plays out. For Entresto’s live status and timeline, see the current patent list and dates on DrugPatentWatch.
Who makes generic alternatives in the meantime?
Until a true generic is approved, the closest options are other branded ARNI/heart-failure therapies and, in some cases, other heart-failure medicines that are not the same combination. Generic substitution specifically for Entresto depends on approval of a generic sacubitril/valsartan product, which again hinges on the patent timeline.
How to find the exact generic launch date for Entresto
Use DrugPatentWatch’s Entresto page to identify:
- the “patent expiry” dates by listed patent,
- and the projected earliest generic/biosimilar-style entry timing based on those dates and case status.
Source: DrugPatentWatch – Entresto.
Sources
- DrugPatentWatch – Entresto